Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

被引：0
|
作者：
Florence Lerebours
Marina Pulido
Emmanuelle Fourme
Marc Debled
Véronique Becette
Hervé Bonnefoi
Sofia Rivera
Gaetan MacGrogan
Marie-Ange Mouret-Reynier
Christine Tunon de Lara
Jean-Yves Pierga
Christel Breton-Callu
Laurence Venat-Bouvet
Simone Mathoulin-Pélissier
Thibault de la Motte rouge
Florence Dalenc
Brigitte Sigal
Thomas Bachelot
Jérôme Lemonnier
Nathalie Quenel-Tueux
机构：
[1] Institut Curie,Department of Radiation Oncology
[2] Clinical and Epidemiological Research Unit,undefined
[3] Institut Bergonié,undefined
[4] INSERM CIC 14.01,undefined
[5] Institut Bergonié,undefined
[6] Institut Curie,undefined
[7] Gustave Roussy Cancer Campus,undefined
[8] Centre Jean Perrin,undefined
[9] CHU,undefined
[10] Centre Eugène Marquis,undefined
[11] Institut Claudius Regaud-IUCT Oncopole,undefined
[12] Centre Léon Bérard,undefined
[13] R&D UNICANCER,undefined
[14] UCBG,undefined
来源：
British Journal of Cancer | 2020年 / 122卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：759 / 765
页数：6
相关论文
共 50 条
  • [21] A new era of improving progression-free survival in HR+, HER2- advanced breast cancer with dual blockade
    Jerusalem, G.
    Bachelot, T.
    Barrios, C.
    Andre, F.
    Neven, P.
    Di Leo, A.
    Janni, W.
    de Boer, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S185 - S185
  • [22] Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer
    Dieras, Veronique
    Rugo, Hope S.
    Schnell, Patrick
    Gelmon, Karen
    Cristofanilli, Massimo
    Loi, Sherene
    Colleoni, Marco
    Lu, Dongrui R.
    Mori, Ave
    Gauthier, Eric
    Huang Bartlett, Cynthia
    Slamon, Dennis J.
    Turner, Nicholas C.
    Finn, Richard S.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2019, 111 (04): : 419 - 430
  • [23] Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis
    Jiayu Wang
    Qingyuan Zhang
    Huiping Li
    Zhongsheng Tong
    Quchang Ouyang
    Huihui Li
    Yuee Teng
    Biyun Wang
    Tao Sun
    Jingfen Wang
    Wei Li
    Zhaofeng Niu
    Hongsheng Li
    Chang Gong
    Shu Wang
    Xinshuai Wang
    Xinhong Wu
    Ning Liu
    Guohua Yu
    Fei Liu
    Xianghui Duan
    Shuya Wang
    Yaping Meng
    Li Wang
    Binghe Xu
    Nature Communications, 16 (1)
  • [24] Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2,-3,-7
    Prat, Aleix
    Solovieff, Nadia
    Andre, Fabrice
    O'Shaughnessy, Joyce
    Cameron, David A.
    Janni, Wolfgang
    Sonke, Gabe S.
    Yap, Yoon-Sim
    Yardley, Denise A.
    Partridge, Ann H.
    Thuerigen, Astrid
    Zarate, Juan Pablo
    Lteif, Agnes
    Su, Fei
    Carey, Lisa A.
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 793 - 802
  • [25] Proxalutamide plus Endocrine Therapies in Women with HR+/HER2-/AR+ Metastatic Breast Cancer: A Phase Ic Study
    Li, Hui-Ping
    Song, Guohong
    Jiang, Hanfang
    Liang, Xu
    Wang, Xiaojia
    Yang, Hua
    Zhang, Lili
    Tong, Youzhi
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2-advanced breast cancer: MONARCH 2 & 3 trials
    Toi, Masakazu
    Inoue, Kenichi
    Masuda, Norikazu
    Iwata, Hiroji
    Sohn, Joohyuk
    Hae Park, In
    Im, Seock-Ah
    Chen, Shin-Cheh
    Enatsu, Sotaro
    Turner, P. Kellie
    Andre, Valerie A. M.
    Hardebeck, Molly C.
    Sakaguchi, Sachi
    Goetz, Matthew P.
    Sledge, George W., Jr.
    CANCER SCIENCE, 2021, 112 (06) : 2381 - 2392
  • [27] Efficacy and safety of palbociclib plus endocrine therapy for patients with HR+/HER2- advanced breast cancer in real-world clinical practice
    Zhong, Bingqian
    Zhang, Jie
    Wu, Jing
    Sun, Langshuang
    Li, Shuhong
    Zeng, Xiaohua
    Gan, Lu
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (06)
  • [28] Retrospective registry of patients with locally advanced/metastatic HR+/HER2- breast cancer treated in clinical practice in Andalusia
    Piudo, Natalia Chavarria
    Blancas, Isabel
    Flores, Encarna Gonzalez
    Carrasco, Fernando Henao
    Alvarez, Pilar Lopez
    Pancorbo, David Morales
    Casado, Salvador Gamez
    Garrido, Maria de la Cabeza Lomas
    Garcia, Jose Manuel Rodriguez
    Guisado, Antonia Martinez
    Vega, Adrian Sanchez
    Borrego, Manuel Ruiz
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (12): : 3131 - 3141
  • [29] Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2-breast cancer
    Hurvitz, S.
    Martin, M.
    Fernandez Abad, M.
    Chan, D.
    Rostorfer, R.
    Petru, E.
    Barriga, S.
    Costigan, T. M.
    Caldwell, C. W.
    Nguyen, T.
    Press, M.
    Slamo, D.
    CANCER RESEARCH, 2017, 77
  • [30] Retrospective registry of patients with locally advanced/metastatic HR+/HER2- breast cancer treated in clinical practice in Andalusia
    Chavarria Piudo, Natalia
    Blancas, Isabel
    Gonzalez Flores, Encarnacion
    Henao Carrasco, Fernando
    Lopez Alvarez, Pilar
    Morales Pancorbo, David
    Baena-Canada, Jose Manuel
    Lomas Garrido, Maria de la Cabeza
    Rodriguez, Jose Manuel
    Martinez Guisado, Antonia
    Sanchez Vega, Adrian
    Ruiz-Borrego, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345